Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that cyclosporine showed a trend toward improving alopecia areata symptoms compared to placebo, but the difference was not statistically significant.

This study suggests that the COX-2 enzyme plays a role in hair follicle biology, as transgenic overexpression in mice induced hair follicle cycling disturbances and alopecia, which was mitigated by COX-2 inhibition.

This study found that while cyclophosphamide remains effective for severe autoimmune conditions, it is associated with gastrointestinal side effects, infections, some cases of irreversible amenorrhoea, and a higher risk of malignancies, emphasizing the need for long-term monitoring.

In this study, rituximab treatment for children with steroid-dependent nephrotic syndrome was associated with a longer remission time and fewer side effects compared to cyclophosphamide.

This article reviews the use of cyclosporine in dermatological conditions, noting its benefits in treating various skin diseases despite known adverse effects like nephrotoxicity and hypertension, and highlights its preferred use over other immunosuppressants due to an early therapeutic response and a good safety profile.

In this study, cyclosporin effectively controlled cases of granulomatous folliculitis, furunculosis, sebaceous adenitis in cats, and alopecia areata in a dog, positioning it as a promising alternative to glucocorticoids in veterinary dermatology.

In this study, a combined therapy of Cyclosporine A and ketoconazole resolved anal furunculosis in dogs within 10 weeks, but recurrences were noted in about 37% of cases.

This study introduces a mouse model of cyclophosphamide-induced alopecia, which effectively replicates human chemotherapy-induced hair loss and can be pharmacologically manipulated to study hair regrowth patterns.

This study found that overexpressing PKCδ in transgenic mice did not reduce squamous cell carcinoma development induced by UV radiation, despite its effectiveness against TPA-promoted cancer in these mice.

This study found that oral cyclosporin A increased hair growth in nude mice, while minoxidil did not have the same effect.

This study found that cyclosporine A treatment at 5 mg/kg/day may reduce inflammation and promote gland regeneration in dogs with sebaceous adenitis, though symptoms returned when treatment stopped.

This study observed that rat vibrissa hair follicles cultured in vitro showed morphological changes suggesting cyclical activity but remained blocked in the pro-anagen stage.

This article discusses the autoimmune pathogenesis of alopecia areata and reviews the use of immunosuppressive therapies in its treatment, but it does not provide new clinical results.

Topical cyclosporine led to significant hair growth in some men with male pattern baldness.

This article reviews the use of cyclophosphamide in kidney disease treatment, highlighting significant concerns about long-term risks of cancer and infertility, and stress strategies for dose reduction and side effect mitigation; no new study results are presented.

This study found that cyclosporine A may lead to partial hair regrowth in 50% of patients with severe alopecia areata who do not respond to standard treatments.

This study provides evidence that Cyclosporine A inhibits catagen development in human hair follicles, suggesting different underlying mechanisms from those observed in rodent studies.

This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.

In this study, treating refractory alopecia universalis with low-dose cyclosporine A and prednisolone improved symptoms, with no recurring alopecia six months post-treatment and enhancements in immunologic function.

This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.

This study found that mimosine dipeptide enantiomers inhibit melanogenesis and cyclooxygenase enzymes in B16F10 melanoma cells, suggesting potential for treating skin hyperpigmentation and inflammation.

This study found that cyclosporin A treatment in young nude mice induced dose-dependent hair growth, which stopped after treatment cessation, but did not result in hair growth in older mice.

This study found that cyclophosphamide-induced hair follicle damage in C3H mice could be remodelled into intact anagen hair follicles with topical cyclosporin A, especially in anagen IV stage follicles.

This review examines the role of cyclodextrins in improving the solubility, stability, and bioavailability of steroid drugs but does not report new experimental findings.

This study found that Activin B at 10 ng/mL may promote vibrissae follicle growth in mice by enhancing hair matrix cell proliferation and cell cycle progression via ERK signaling pathways.

This study found that the dimethyl-β-cyclodextrin inclusion system significantly improved the solubility and bioavailability of finasteride compared to the drug alone, enhancing its absorption rate.

This report describes the unexpected development of alopecia areata in kidney-pancreas transplant recipients undergoing cyclosporine-based immunosuppressive therapy, suggesting a complex relationship between the treatment and disease.

This pilot study suggests that topical cyclosporin may delay hair shedding and potentially treat alopecia, based on observations in a human scalp skin graft model on mice.

This study found that topical cyclosporine significantly prolonged the survival of skin allografts in a rat model, with maximum effectiveness achieved through local direct application.

This study found that RhoA influences embryonic stem cell proliferation through the PKN1-cyclin D1 pathway in vitro, suggesting RhoA as a potential target for wound healing therapies.